Integrated Clinical Trial Services, Inc.

Based in Iowa, US, and founded in 2005 by co-founders Joe and Kristine Majors, Integrated Clinical Trial Services, Inc. conducts clinical trials to evaluate investigational medications for pharmaceutical companies. In October 2024, Eximia Research Network, LLC, a portfolio company of VSS Capital Partners, acquired Integrated Clinical Trial Services, Inc.   Integrated Clinical Trial Services, Inc.

(ICTS) specializes in conducting clinical trials to evaluate investigational medications on behalf of pharmaceutical companies. The core offerings include participation in studies targeting conditions such as diabetes, fibromyalgia, common warts, and chronic pain, among others. ICTS provides a platform for volunteer patients to engage in clinical trials without the need for insurance or payment for treatments, thus enhancing patient comfort and safety throughout the trial process. The company operates within the Midwest region of the United States, serving a diverse clientele that includes pharmaceutical firms and individuals seeking innovative health solutions.

By facilitating trials that adhere to FDA-approved protocols, ICTS aims to contribute to the advancement of new treatments while addressing unmet medical needs in various therapeutic areas. Revenue generation at Integrated Clinical Trial Services, Inc. primarily occurs through partnerships with pharmaceutical companies that sponsor clinical trials. Clients engage ICTS to conduct evaluations of investigational medications, leading to structured agreements outlining the terms of participation and compensation.

The financial model is generally B2B, with pharmaceutical firms compensating ICTS for their expertise in managing clinical trials and ensuring participant compliance with study protocols.